- $21.09m
- $16.78m
- $14.24m
- 65
- 39
- 82
- 66
Annual balance sheet for Nephros, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 4.17 | 8.25 | 6.97 | 3.63 | 4.31 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.04 | 1.36 | 1.64 | 1.29 | 1.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 8.3 | 15.2 | 13.6 | 8.26 | 8.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.19 | 1.33 | 1.1 | 1.1 | 1.96 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 11.6 | 18.5 | 17.6 | 11 | 11.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.43 | 1.32 | 2.39 | 1.41 | 2.11 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.95 | 5.99 | 5.96 | 5.41 | 3.5 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 4.67 | 12.5 | 11.7 | 5.59 | 8.36 |
| Total Liabilities & Shareholders' Equity | 11.6 | 18.5 | 17.6 | 11 | 11.9 |
| Total Common Shares Outstanding |